Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Evidence of antitumor activity found for Xyotax in recurrent ovarian cancer

Feb. 3, 2003

Study suggests Active Biotech's TASQ drug is suitable for oral dosing

Jan. 31, 2003

Phase II study to evaluate Aptosyn combination regimen in prostate cancer

Jan. 31, 2003

Replicon NeuroTherapeutics awarded grant for replicon development

Jan. 31, 2003

Apoptosis-inducing glucose derivatives prepared and tested by Nisshin Seifun and Kyorin team

Jan. 31, 2003

Schering presents new inhibitors of CDK and/or GSK-3

Jan. 31, 2003

Tarceva phase III trial in pancreatic cancer achieves target enrollment

Jan. 30, 2003

Triapine enters further phase II trial in prostate cancer

Jan. 29, 2003

Onyx discontinues development of ONYX-015 to focus on Bay-43-9006

Jan. 29, 2003

New data on once-daily lonafarnib in patients with advanced solid tumors

Jan. 28, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...